New York State Common Retirement Fund bought a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 15,000 shares of the biopharmaceutical company’s stock, valued at approximately $310,000. New York State Common Retirement Fund owned about 0.09% of Assembly Biosciences at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Nationwide Fund Advisors bought a new position in shares of Assembly Biosciences in the 2nd quarter valued at about $161,000. TIAA CREF Investment Management LLC bought a new position in Assembly Biosciences during the 2nd quarter worth approximately $930,000. Teachers Advisors LLC bought a new position in Assembly Biosciences during the 2nd quarter worth approximately $515,000. AXA bought a new position in Assembly Biosciences during the 2nd quarter worth approximately $2,477,000. Finally, Wells Fargo & Company MN bought a new position in Assembly Biosciences during the 2nd quarter worth approximately $213,000. 62.19% of the stock is currently owned by institutional investors.

In related news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $29.55, for a total transaction of $29,550.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 19.60% of the stock is owned by company insiders.

WARNING: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/15000-shares-in-assembly-biosciences-inc-asmb-acquired-by-new-york-state-common-retirement-fund/1713280.html.

Assembly Biosciences, Inc. (NASDAQ:ASMB) opened at $35.54 on Friday. Assembly Biosciences, Inc. has a one year low of $11.07 and a one year high of $36.90.

Several research analysts recently weighed in on the stock. Chardan Capital reissued a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th. Zacks Investment Research raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research note on Wednesday. BidaskClub raised shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 3rd. Finally, Jefferies Group LLC assumed coverage on shares of Assembly Biosciences in a research note on Wednesday, November 8th. They set a “buy” rating and a $50.00 price objective on the stock.

Assembly Biosciences Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences, Inc. (NASDAQ:ASMB).

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.